Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-18
2007-12-18
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S401000
Reexamination Certificate
active
11013326
ABSTRACT:
The use of selective imidazoline receptor agonists, such as moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 and BU-98008, and their physiologically compatible acid addition salts in pharmaceutical preparations for the treatment and/or inhibition of functional disorders and/or diseases in larger mammals or humans which require inhibition or reduction of the activity of proteins which regulate the intracellular pH value and which belong to the superfamily of bicarbonate transporters, in particular the treatment or inhibition of clinical conditions of bones which are caused by an undesirable amount of bone resorption, such as osteoporosis; of diseases of the gastrointestinal tract, such as gastric ulcers; and of neuronal and/or neuropsychiatric diseases associated with a pathologically altered (especially increased) neuronal activity, such as depression, Alzheimer's disease, eating disorders and schizophrenia.
REFERENCES:
patent: 3988464 (1976-10-01), Malen et al.
patent: 4102890 (1978-07-01), Malen et al.
patent: 4323570 (1982-04-01), Stenzel et al.
patent: 4952410 (1990-08-01), Armah et al.
patent: 5492912 (1996-02-01), Godfroid et al.
patent: 5500426 (1996-03-01), Godfroid et al.
patent: 5686477 (1997-11-01), Jarry et al.
patent: 5703118 (1997-12-01), Durand et al.
patent: 5712283 (1998-01-01), Kaan et al.
patent: 5732717 (1998-03-01), Watanabe et al.
patent: 5741796 (1998-04-01), Hartman et al.
patent: 5804587 (1998-09-01), Cupps et al.
patent: 5925665 (1999-07-01), Payard et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6054461 (2000-04-01), Fairbanks et al.
patent: 6117879 (2000-09-01), Fairbanks et al.
patent: 6204271 (2001-03-01), Fairbanks et al.
patent: 6300336 (2001-10-01), Eeckhout et al.
patent: 6300366 (2001-10-01), Bousquet et al.
patent: 6475752 (2002-11-01), Lal et al.
patent: 6777394 (2004-08-01), Prell
patent: 2001/0053777 (2001-12-01), Brecht
patent: 2002/0161191 (2002-10-01), Feder et al.
patent: 2003/0181354 (2003-09-01), Abdulrazik
patent: 2 362 754 (1974-07-01), None
patent: 28 49 537 (1980-05-01), None
patent: 0 638 568 (1974-07-01), None
patent: 0 710 658 (1996-05-01), None
patent: 0 638 568 (1996-10-01), None
patent: 0 740 936 (1996-11-01), None
patent: 0 820 988 (1998-01-01), None
patent: 0 846 688 (1998-06-01), None
patent: 1 038 526 (2000-09-01), None
patent: 1 101 756 (2001-05-01), None
patent: WO 00/02878 (2000-01-01), None
patent: WO 01/41764 (2001-06-01), None
(“Osteoporosis: No Cure, But Treatment Offer Relief”, www.ucihealth.com, 2006.
“Boning Up on Osteoporosis”, www.fda.gov, 2004.
“Rheumatoid Arthritis treatments”, Matsumoto et al., www.hopkins-arthritis.com, 2006.
“Medical Treatment Decisions for People with Paget's Disease of Bone”, www.niams.nih.gov, 2005.
I1 imidzoline receptor agonists, Ian Musgrave, ian.Musgrave at med.monash.edu.au, Aug. 1, 1996.
(“Pharmacological and molecular discrimination of brain I2-imidazoline receptor subtypes”, Olmos et al., Naunym Schmiedebergs Arch Pharmacol., 1996, abstract, 354 (6):709-16.
Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for card ioprotective therapy: progress, problems and prospects. J Am Coll Cardiol Mar. 6, 2002;39(5):747-53.
Bock et al. (1999) Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Naunyn Schmiedebergs Arch Pharmacol. 359:262-71.
Bonnet et al. (2000) Alteration of intracellular pH and activity of CA3-pyramidal cells in guinea pig hippocampal slices by inhibition of transmembrane acid extrusion. Brain Res. 872:116-24.
Boron & De Weer (1976) Intracellular pH transients in squid giant axons caused by CO2, NH3, and metabolic inhibitors. J Gen Physiol. 67:91-112.
Boron (2001) Sodium-coupled bicarbonate transporters. JOP 24(Suppl):176-81.
Bosman GJ, Renkawek K, Van Workum FP, Bartholomeus IG, Marini S, De Grip WJ. Neuronal anion exchange proteins in Alzheimer's disease pathology. J Neural Transm Suppl 1998;54:248-57.
Brilla et al. (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell Cardiol. 26:809-820.
Canzoniero et al. (1996) Recovery from NMDA-induced intracellular acidification is delayed and dependent on extracellular bicarbonate. Am J Physiol. 270:C593-9.
Chambers et al. (1985) The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 116:234-9.
Emsberger (2000) Pharmacology of moxonidine: an 11-imidazoline receptor agonist. J Cardiovasc Pharmacol. 35:S27-41.
Gary B. Glavin & Donald D. Smyth, Effects of the selective I imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats, British Journal of Pharmacology (1995)114, 751-754.
Hall et al. (1989) Optimal bone resorption by isolated rat osteoclasts requires chloride/bicarbonate exchange, Calcif Tissue Int. 45:378-80.
Hieble & Ruffolo (1995) Possible structural and functional relationships between imidazoline receptors and alpha 2-adrenoceptors. Ann N Y Acad Sci. 763:8-21.
Lagadic-Gossmann, D.; Prigent, K. Le: Baut, G. Le; Caignard, D. H. Renard, P. Scalbert, E.; Feuvray, D. (1996) Effects of S20787 on pHi-Regulating Mechanisms in Isolated Rat Ventricular Myocytes vol. 28(4),pp. 547-552 Lippincott-Raven Publishers.
Le Bihan et al. (1999) Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4dialkyl-,1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines and isosteric analogues of imidazoline. J Med Chem. 42:1587-603.
Muallem et al. (1988) Activation of the Na+/H+ and Cl-/HCO3- exchange by stimulation of acid secretion in the parietal cell. J Biol Chem. 263:14703-11.
D.J. Nutt, N. French, S. Handly, A. Hudson, S. Husbands, H. Jackson, S. Jordan, M.D. Lalies, J. Lewis, L. Lione, N. Mallard and J. Pratt. Functional Studies of Specific Imidazoline-2 Receptor Ligands, Annals New York Academy of Sciences, 125-39.
Poisson D., Montaron, Garrigue, MUh & Sannajust Neuroprotective Efects Of Rilmendine On Neuronal And Glial Cell Injuries Induced By Hypoxia, pl53.
Puceat (1999) PHi regulatory ion transporters: an update on stricture, regulation and cell function, Review, Cell Mol Life Sci, 55(10), 1216-25.
D.J. Reis, MD, S. Regunathan, Phd, E.V. Golanov, MD, PhD and D.L. Feinstein, PhD, Protection of Focal Ischemic Infarction by Rilmenidine in the Animal: Evidence That Interactions with Central Imidazoline Receptors May Be Neuroprotective, The American Journal of Cardiology, 74 (1994) 25A.
Romero et al. (2000) Cloning and characterization of a NA+-driven anion exchanger (NDAE1). A new bicarbonate transporter. J Biol Chem 275:24552-9.
Rondu et al. (1997) Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzylN′-(arylalkyl)-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines. J Med Chem. 40:3793-803.
Eberhard Schlatter, Jeva Ankorina-Stark, Sabine Haxelmans and Helge Hohage Moxonidine inhibits Na+/H+ exchange in proximal tubule cells and cortical collecting duct Kidney International, vol. 52 (1997), pp. 454-459.
Schann et al. (2001) Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrro1-2-yl)amine (LNP 509) , an 11 imidazoline receptor selective ligand with hypotensive activity. J Med Chem. 44:1588-93.
Takagi & Okabe (1968) The effects of drugs on the production and recovery processes of the stress ulcer. Jpn J Pharmacol. 18:9-18.
Takahashi & Copenhagen (1996) Modulation of neuronal function by intracellular pH. Neurosci Res. 24:109-16.
Teti et al. (1989) Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J Clin Invest. 83:227-33.
Trapp et al
Eisele Bernd
Jaeger Bodo
Maisch Bernhard
Rupp Heinz
Ziegler Dieter
Crowell & Moring LLP
Kwon Brian
Solvay Pharmaceuticals GmbH
LandOfFree
Method for the treatment of diseases requiring inhibition or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of diseases requiring inhibition or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of diseases requiring inhibition or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3894688